TY - JOUR
T1 - Association of factor XIII Val34Leu polymorphism and coronary artery disease
T2 - A meta-analysis
AU - Jung, Jae Hyun
AU - Song, Gwan Gyu
AU - Kim, Jae Hoon
AU - Seo, Young Ho
AU - Choi, Sung Jae
N1 - Funding Information:
This study was supported by Korea University Medical College grant.
Publisher Copyright:
© 2017 Via Medica.
PY - 2017
Y1 - 2017
N2 - Background: Factor XIII plays an important role in the stabilization of the linkage between fibrins and in the pathophysiology of coronary artery disease (CAD). The association between factor XIII Val34Leu polymorphism and CAD risk remains controversial. Methods: We conducted a meta-analysis of 36 studies involving 26,940 cases and 34,694 controls. Subgroup analyses were performed with division of data into disease (myocardial infarction [MI], CAD without MI), age, and sex. Results: Factor XIII Val34Leu polymorphism was significantly associated with ove all CAD risk (odds ratio [OR] = 1.09, 95% confidence interval [CI] = 1.03–1.06, p = 0.004) and MI risk (OR = 1.15, 95% CI 1.07–1.25, p = 0.0003), but not with CAD without MI risk (OR = 1.00, 95% CI 0.87–1.15, p = 0.96). In the subgroup analysis by age and sex, there was no association between Val34Leu polymorphism and CAD. Conclusions: This meta-analysis found that factor XIII Val34Leu polymorphism was associated with CAD risk, especially MI, but not with CAD without MI. In addition, age and sex did not affect the relationship between factor XIII Val34Leu polymorphism and CAD risk.
AB - Background: Factor XIII plays an important role in the stabilization of the linkage between fibrins and in the pathophysiology of coronary artery disease (CAD). The association between factor XIII Val34Leu polymorphism and CAD risk remains controversial. Methods: We conducted a meta-analysis of 36 studies involving 26,940 cases and 34,694 controls. Subgroup analyses were performed with division of data into disease (myocardial infarction [MI], CAD without MI), age, and sex. Results: Factor XIII Val34Leu polymorphism was significantly associated with ove all CAD risk (odds ratio [OR] = 1.09, 95% confidence interval [CI] = 1.03–1.06, p = 0.004) and MI risk (OR = 1.15, 95% CI 1.07–1.25, p = 0.0003), but not with CAD without MI risk (OR = 1.00, 95% CI 0.87–1.15, p = 0.96). In the subgroup analysis by age and sex, there was no association between Val34Leu polymorphism and CAD. Conclusions: This meta-analysis found that factor XIII Val34Leu polymorphism was associated with CAD risk, especially MI, but not with CAD without MI. In addition, age and sex did not affect the relationship between factor XIII Val34Leu polymorphism and CAD risk.
KW - Coagulation
KW - Coronary artery disease
KW - Factor XIII A Val34Leu
KW - Meta-analysis
KW - Myocardial infarction
UR - http://www.scopus.com/inward/record.url?scp=85014068181&partnerID=8YFLogxK
U2 - 10.5603/CJ.a2016.0070
DO - 10.5603/CJ.a2016.0070
M3 - Article
C2 - 27665853
AN - SCOPUS:85014068181
SN - 1897-5593
VL - 24
SP - 74
EP - 84
JO - Cardiology Journal
JF - Cardiology Journal
IS - 1
ER -